Exhibit 99.3

1 NSCLC = Non-small cell lung cancer 2 Program is not HLA restricted (i.e. universal for all populations). *ID = Infectious diseases Leading bispecific TCR pipeline Candidate Target (HLA type) Indication Pre IND Phase 1 Phase 2 Phase 3 Approved gp100-A02 Uveal (ocular) melanoma Adjuvant uveal (ocular) melanoma 2L+ advanced cutaneous melanoma PRAME Programs Brenetafusp (PRAME-A02) 1L advanced cutaneous melanoma Combos Ovarian, NSCLC1 Additional solid tumors IMC-P115C (PRAME-A02-HLE) Multiple solid tumors IMC-R117C PIWIL1-A02 Colorectal and GI cancers IMC-M113V Gag-A02 Human Immunodeficiency Virus (HIV) IMC-S118AI PPI x PD1-A02 Type 1 Diabetes IMC-U120AI CD1a x PD1 (non-HLA restricted)2 Atopic Dermatitis Oncology ID* Autoimmune TEBE-AM PRISM-MEL-301 ATOM sponsored by